Facebook
Instagram
Pinterest
Reddit
Tumblr
X
Youtube
Home
About
News
Events
Shop
Directory
Contact Us
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
PsyNews.com
Home
About
News
Events
Shop
Directory
Contact Us
Home
Featured
Page 135
Featured
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Pα+ Psychedelic Bulletin #225: Q1 Lobbying Update; Individual vs. Group MDMA Therapy Study Launches; Australia Loosens Psychedelics Access Regulations; VA Launches “New” MDMA Trial
Three Brain Injuries, One Iboga Protocol, and What It Tells Us
The War on Drugs Was Never About Drugs. Psychedelic Healing Must Reckon With That.
A Dispatch from APA’s Annual Meeting: Psychedelics Return at an Awkward Moment for American Psychiatry
Momentum Amidst Tumult: The FDA Reshuffle, Approval Timelines, and the Compass-Usona Race
Optimi Health Announces Re-Appointments to Board of Directors
Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for...
PT381 – DMT, Hierarchies of Complexity, and Reality Switch Technologies
PharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine for Prevention...
Psychedelic Bulletin #128: atai Results Disappoint; MAPS Confirmatory Phase 3 Study...
GH Research Reports Third Quarter 2022 Financial Results and Provides Business...
Legally Psychedelic: The Regulatory Environment from Oregon to Colorado
Psychedelics Weekly – Psilocybin-Assisted Psychotherapy for I.B.S., NY Aims to Legalize,...
atai Life Sciences Announces Results from Phase 2a Trial of PCN-101...
atai’s PCN-101 Candidate Fails to Meet Primary Endpoint in Heavily-Anticipated Phase...
Load more